Not to be a party-pooper. Management seems to be confident of stitching up a nice partnership deal. What is it for the big pharmas to keep pushing the timeline to take advantage of the diminishing cash position of Bionomics? Is the management dealing with more than one partner simulataneously and thus setting up a proxy bidding war?
Dont get me wrong. Time is of essence here.
Do they hava a backup plan to dilute the stock even further and go alone to phase 2 trials? If they are so confident of the compound, they can design a trial with FDA to get approval based on phase 2 itself.
Of course with scant pipelines for major pharmas, there is bound to be enormous interest in BNC210. These are exciting as well as nervous tmes if you own the stock.
BNO Price at posting:
62.6¢ Sentiment: Hold Disclosure: Held
